These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 9609216

  • 1. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
    Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, d'Azemar P, Sagnard L.
    Thromb Haemost; 1998 May; 79(5):897-901. PubMed ID: 9609216
    [Abstract] [Full Text] [Related]

  • 2. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H, Marchetti O, Haeberli A, Mombelli G.
    Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
    [Abstract] [Full Text] [Related]

  • 3. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [Abstract] [Full Text] [Related]

  • 4. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF, Neuhart E.
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [Abstract] [Full Text] [Related]

  • 5. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
    Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, Michalak J, Ciesielski L, Mackiewicz Z, Czestochowska E, Zawilska K, Cencora A.
    Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
    [Abstract] [Full Text] [Related]

  • 6. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV, CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.
    N Engl J Med; 2001 Mar 01; 344(9):626-31. PubMed ID: 11228276
    [Abstract] [Full Text] [Related]

  • 7. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
    Ramacciotti E, Araújo GR, Lastoria S, Maffei FH, Karaoglan de Moura L, Michaelis W, Sandri JL, Dietrich-Neto F, CLETRAT Investigators.
    Thromb Res; 2004 Mar 01; 114(3):149-53. PubMed ID: 15342210
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P, Carnovali M, Marchiori A, Galilei Investigators.
    Arch Intern Med; 2004 May 24; 164(10):1077-83. PubMed ID: 15159264
    [Abstract] [Full Text] [Related]

  • 9. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH.
    N Engl J Med; 1996 Mar 14; 334(11):682-7. PubMed ID: 8594426
    [Abstract] [Full Text] [Related]

  • 10. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S, Breyer HG, Bacher HP, Fareed J, Misselwitz F, Victor N, Weber J, ECHOS Trial Group.
    Int Angiol; 2006 Dec 14; 25(4):335-42. PubMed ID: 17164738
    [Abstract] [Full Text] [Related]

  • 11. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Couturaud F, Julian JA, Kearon C.
    Thromb Haemost; 2001 Oct 14; 86(4):980-4. PubMed ID: 11686355
    [Abstract] [Full Text] [Related]

  • 12. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
    Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d'Azemar P, Büller HR, ten Cate JW, Hoek JA, van der Meer J, van der Heul C, Turpie AG, Haley S, Sicurella A, Gent M.
    Thromb Haemost; 1996 Feb 14; 75(2):233-8. PubMed ID: 8815566
    [Abstract] [Full Text] [Related]

  • 13. Low-molecular-weight heparin for the treatment of acute ischemic stroke.
    Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A.
    N Engl J Med; 1995 Dec 14; 333(24):1588-93. PubMed ID: 7477193
    [Abstract] [Full Text] [Related]

  • 14. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV, Howes J, Sharma V, Kadziola Z.
    Thromb Haemost; 2000 Apr 14; 83(4):523-9. PubMed ID: 10780310
    [Abstract] [Full Text] [Related]

  • 15. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S.
    Arch Intern Med; 1993 Jul 12; 153(13):1541-6. PubMed ID: 8391792
    [Abstract] [Full Text] [Related]

  • 16. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
    Mismetti P, Mille D, Laporte S, Charlet V, Buchmüller-Cordier A, Jacquin JP, Fournel P, Dutrey-Dupagne C, Decousus H, CIP Study Group.
    Haematologica; 2003 Jan 12; 88(1):67-73. PubMed ID: 12551829
    [Abstract] [Full Text] [Related]

  • 17. The effect of low molecular weight heparin on survival in patients with advanced malignancy.
    Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Büller HR.
    J Clin Oncol; 2005 Apr 01; 23(10):2130-5. PubMed ID: 15699479
    [Abstract] [Full Text] [Related]

  • 18. [Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].
    Lévesque H, Cailleux N, Vasse D, Legallicier B, Moore N, Borg JY, Hantute N, Thuillez C, Courtois H.
    Therapie; 1994 Apr 01; 49(2):101-5. PubMed ID: 7817331
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty.
    Colwell CW, Spiro TE.
    Clin Orthop Relat Res; 1995 Oct 01; (319):215-22. PubMed ID: 7554633
    [Abstract] [Full Text] [Related]

  • 20. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
    Perhoniemi V, Vuorinen J, Myllynen P, Kivioja A, Lindevall K.
    Ann Chir Gynaecol; 1996 Oct 01; 85(4):359-63. PubMed ID: 9014067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.